ViewRay - VRAY Stock Forecast, Price & News

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

ViewRay Stock Up 2.9 %

Shares of ViewRay stock traded up $0.10 on Monday, reaching $3.51. 13,930 shares of the stock were exchanged, compared to its average volume of 1,450,473. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.66 and a current ratio of 3.04. The firm's 50 day moving average is $2.89 and its 200-day moving average is $3.38. ViewRay has a one year low of $2.39 and a one year high of $8.25.

ViewRay (NASDAQ:VRAY - Get Rating) last released its earnings results on Thursday, May 5th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. ViewRay had a negative return on equity of 75.54% and a negative net margin of 131.20%. The firm had revenue of $18.88 million during the quarter, compared to analysts' expectations of $15.62 million. During the same period in the prior year, the company earned ($0.17) earnings per share. The company's quarterly revenue was up 21.6% on a year-over-year basis. On average, sell-side analysts forecast that ViewRay will post -0.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VRAY has been the subject of a number of analyst reports. Piper Sandler dropped their price target on shares of ViewRay from $7.00 to $6.00 and set an "overweight" rating for the company in a research report on Wednesday, August 3rd. BTIG Research dropped their price objective on ViewRay from $9.00 to $8.00 and set a "buy" rating for the company in a report on Friday, June 24th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $7.00.

Insider Buying and Selling

In other ViewRay news, Director Brian K. Roberts bought 16,000 shares of the firm's stock in a transaction on Wednesday, May 18th. The shares were purchased at an average price of $2.98 per share, for a total transaction of $47,680.00. Following the completion of the transaction, the director now directly owns 147,761 shares in the company, valued at approximately $440,327.78. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Scott William Drake purchased 40,000 shares of the stock in a transaction dated Tuesday, May 10th. The stock was bought at an average cost of $2.61 per share, for a total transaction of $104,400.00. Following the completion of the acquisition, the chief executive officer now owns 3,994,730 shares of the company's stock, valued at $10,426,245.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Brian K. Roberts acquired 16,000 shares of the business's stock in a transaction that occurred on Wednesday, May 18th. The shares were purchased at an average cost of $2.98 per share, for a total transaction of $47,680.00. Following the acquisition, the director now owns 147,761 shares in the company, valued at $440,327.78. The disclosure for this purchase can be found here. Insiders acquired a total of 1,221,000 shares of company stock worth $3,125,180 in the last ninety days. 2.50% of the stock is owned by insiders.